Kiniksa Pharmaceuticals International (KNSA) Liabilities and Shareholders Equity (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) reported Liabilities and Shareholders Equity of $896.11 million for Q2 2026, up 35.5% from $661.15 million a year earlier and up 8.6% from the prior quarter.
Powered by 
Analysis
Kiniksa Pharmaceuticals International (KNSA) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
At the end of FY2025, Kiniksa Pharmaceuticals International posted Liabilities and Shareholders Equity of $763.63 million, up 31.5% from FY2024.
- Liabilities and Shareholders Equity has increased for four consecutive years, with a five-year compound annual growth rate of 16.9% (FY2020 to FY2025).
- By year, Liabilities and Shareholders Equity came in at $580.55 million in FY2024 (+10.3%), $526.32 million in FY2023 (+14.5%), $459.67 million in FY2022 (+97.5%) and $232.8 million in FY2021 (-33.4%).
- The Q2 2026 figure ranks as the highest quarterly Liabilities and Shareholders Equity in data going back to Q4 2017.
- Year over year, Liabilities and Shareholders Equity has now increased in each of the last 16 quarters, with growth averaging 24.4% over the last eight quarters.
- The high point for year-over-year Liabilities and Shareholders Equity in five years was Q2 2023 (growth of 130.0%); the low point was Q3 2021 (a decline of 34.2%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $825.28 million (Q1 2026), $763.63 million (Q4 2025) and $712.33 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | Kiniksa Pharmaceuticals International | 11.64 Bn | 10.38 Bn | 220.03 Mn | 896.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 896.11 Mn |
| Mar 31, 2026 | 825.28 Mn |
| Dec 31, 2025 | 763.63 Mn |
| Sep 30, 2025 | 712.33 Mn |
| Jun 30, 2025 | 661.15 Mn |
| Mar 31, 2025 | 599.33 Mn |
| Dec 31, 2024 | 580.55 Mn |
| Sep 30, 2024 | 555.30 Mn |
| Jun 30, 2024 | 542.43 Mn |
| Mar 31, 2024 | 519.67 Mn |
| Dec 31, 2023 | 526.32 Mn |
| Sep 30, 2023 | 483.06 Mn |
| Jun 30, 2023 | 484.33 Mn |
| Mar 31, 2023 | 442.86 Mn |
| Dec 31, 2022 | 459.67 Mn |
| Sep 30, 2022 | 459.95 Mn |
| Jun 30, 2022 | 210.58 Mn |
| Mar 31, 2022 | 230.97 Mn |
| Dec 31, 2021 | 232.80 Mn |
| Sep 30, 2021 | 252.86 Mn |
API Access
Kiniksa Pharmaceuticals International Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=KNSA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "KNSA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=KNSA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();